The Library
A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update
Tools
Tools
Tools
Biswas, S., Wrigley, J., East, C., Hern, A., Marshall, A. (Andrea), Dunn, Janet A., Lorigan, P., Middleton, M. (Mark) and Corrie, P.. (2008) A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update. ecancermedicalscience, Vol.2 . p. 108. ISSN 1754-6605
|
Text
WRAP_Marshall_can-2-108.pdf - Published Version Download (927Kb) | Preview |
Official URL: http://dx.doi.org/10.3332/ecancer.2008.108
Abstract
At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of developing metastasis and subsequent disease-related death. Given this, it is important that novel therapies are investigated in the adjuvant melanoma setting. Since angiogenesis is essential for primary tumour growth and the development of metastasis, anti-angiogenic agents are attractive potential therapeutic candidates for clinical trials in the adjuvant setting. Therefore, we initiated a phase II trial in resected high-risk cutaneous melanoma, assessing the efficacy of bevacizumab versus observation. In the interim safety data analysis, we demonstrate that bevacizumab is a safe therapy in the adjuvant melanoma setting with no apparent increase in the surgical complication rate after either primary tumour resection and/or loco-regional lymphadenectomy.
| Item Type: | Journal Article |
|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences |
| Library of Congress Subject Headings (LCSH): | Melanoma -- Treatment, Neovascularization inhibitors, Bevacizumab |
| Journal or Publication Title: | ecancermedicalscience |
| Publisher: | The European Institute of Oncology |
| ISSN: | 1754-6605 |
| Date: | 12 November 2008 |
| Volume: | Vol.2 |
| Page Range: | p. 108 |
| Identification Number: | 10.3332/ecancer.2008.108 |
| Status: | Peer Reviewed |
| Publication Status: | Published |
| Access rights to Published version: | Open Access |
| References: | 1. Sabel MS and Sondak VK (2003) Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma Oncologist 8 5 451–8 PMID 14530498 doi: 10.1634/ theoncologist.8-5-451 2. Mohr P, Weichenthal M and Hauschild A (2003) Adjuvant Therapy in Melanoma Onkologie 26 3 227–33 PMID 12845206 doi: 10.1159/000071617 3. Sosman JA and Puzanov I (2006) Molecular Targets in Melanoma from Angiogenesis to Apoptosis Clin Cancer Res 12 7 pt 2 2376s–2383s PMID 16609062 doi:10.1158/ 1078-0432.CCR-05-2558 4. Molhoek KR, Griesemann H, Shu J et al (2008) Human Melanoma Cytolysis by Combined Inhibition of Mammalian Target of Rapamycin and Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2 Cancer Res 68 11 4392–7 PMID 18519701 doi: 10.1158/0008-5472.CAN-07-5844 5. Ciardiello F, Bianco R, Damiano V et al (2000) Antiangiogenic and Antitumor Activity of Anti- Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Fcator Antisense Oligonucleotide in Human GEO Colon Cancer Cells Clin Cancer Res 6 9 3739–47 PMID 10999768 6. Pinedo HM and Slamon DJ (2000) Introduction: Translational Research: The Role of VEGF in Tumor Angiogenesis Oncologist 5 Suppl 1 1–2 PMID 10804083 doi:10.1634/theoncologist.5-suppl_1-1 7. Scheri R, Morton D, Essner R et al (2006) Molecular profiling of melanoma intransit metastasis identifies VEGF as a therapeutic target Melanoma Res 16 Suppl 1 S16–18 doi:10.1097/00008390-200609001-00028 8. Gorski DH, Leal AD and Goydos JS (2003) Differential expression of Vascular endothelial growth factor: A isoforms at different stages of melanoma progression J Amer Coll Surg 197 3 408–18 PMID 12946796 doi: 10.1016/S1072-7515(03)00388-0 9. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study J Clin Oncol 26 12 2013–9 PMID 18421054 doi: 10.1200/JCO. 2007.14.9930 10. Kerr DJ (2008) Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as firstline treatment Nat Clin Prac Oncol 5 5 250–1 PMID 18382429 doi:10.1038/ncponc1108 11. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer N Engl J Med 357 26 2666–76 PMID 18160686 doi: 10.1056/NEJMoa072113 12. Motzer RJ, Basch E, Escudier B et al (2007) Targeted drugs for metastatic renal cell carcinoma Lancet 370 9605 2071–3 PMID 18156012 doi:10.1016/S0140-6736(07) 61874-1 13. Diaz-Rubio E and Schmoll HJ (2005) The future development of bevacizumab in colorectal cancer Oncology 69 Suppl 3 34–45 PMID 16301834 doi:10.1159/ 000088482 14. Varkar KA, Biber JE, Kefauver C et al (2007) A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma Ann Surg Oncol 14 8 2367–76 PMID 17534686 doi: 10.1245/s10434-007-9389-5 |
| URI: | http://wrap.warwick.ac.uk/id/eprint/49475 |
Actions (login required)
 |
View Item |
